Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms.

We review recent Bayesian network inference methodologies we developed to infer genetic and metabolic pathways associated to oncological drug chemoresistance. Bayesian inference is supported by a rigorous and widely accepted mathematical formalization of predictive analytics. It is an inherently integrative approach allowing the incorporation of prior knowledge and constraints. Moreover, it is recommended to treat noisy data, and large amount of data whose dynamics laws are mostly unknown. We focus on variational Bayesian methods for the inference of stochastic reaction processes and we present a compendium of the recent results of inference of gene and metabolic networks presiding at the development of pancreas cancer resistance to gemcitabine.

[1]  John R. Mackey,et al.  Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions , 2010, Cancers.

[2]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[3]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[4]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[5]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[6]  Edward Chu,et al.  Physicians' Cancer Chemotherapy Drug Manual , 2016 .

[7]  植村 志乃美,et al.  Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer : increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance , 2009 .

[8]  M. Opper,et al.  Chapter 1 Approximate inference for continuous-time Markov processes , 2009 .

[9]  Darren J. Wilkinson.  Stochastic Modelling for Systems Biology , 2006 .

[10]  Anton Crombach,et al.  Efficient Reverse-Engineering of a Developmental Gene Regulatory Network , 2012, PLoS Comput. Biol..

[11]  Minoru Tada,et al.  Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis. , 2005, Oncology reports.

[12]  Ryota Souzaki,et al.  Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. , 2010, Neoplasia.

[13]  Paola Lecca,et al.  Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics , 2012, BMC Systems Biology.

[14]  R. Hyde,et al.  Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). , 2001, Molecular membrane biology.

[15]  D. Gillespie.  A General Method for Numerically Simulating the Stochastic Time Evolution of Coupled Chemical Reactions , 1976 .

[16]  Corrado Priami,et al.  Algorithmic Systems Biology - Computer Science Propels Systems Biology , 2012, Handbook of Natural Computing.

[17]  Kenoki Ohuchida,et al.  Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. , 2008, Anticancer research.

[18]  M. Stephens,et al.  Scalable Variational Inference for Bayesian Variable Selection in Regression, and Its Accuracy in Genetic Association Studies , 2012 .

[19]  V. Anne Smith,et al.  Evaluating functional network inference using simulations of complex biological systems , 2002, ISMB.

[20]  Paola Lecca,et al.  An integrative network inference approach to predict mechanisms of cancer chemoresistance. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[21]  A. Hajri,et al.  Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. , 2009, Neoplasia.

[22]  Zhiwei Wang,et al.  Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations , 2010, Molecular Cancer Therapeutics.

[23]  G. Papoian,et al.  Reverse-engineering of biochemical reaction networks from spatio-temporal correlations of fluorescence fluctuations. , 2010, Journal of theoretical biology.

[24]  Jung-Hsien Chiang,et al.  An integrative approach to identifying cancer chemoresistance-associated pathways , 2011, BMC Medical Genomics.

[25]  Thomas J. Fuchs,et al.  A high-throughput metabolomics method to predict high concentration cytotoxicity of drugs from low concentration profiles , 2011, Metabolomics.

[26]  Pierre Baldi,et al.  Bioinformatics - the machine learning approach (2. ed.) , 2000 .

[27]  E. Giovannetti,et al.  Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer , 2010, The Pharmacogenomics Journal.

[28]  Adam Arkin,et al.  On the deduction of chemical reaction pathways from measurements of time series of concentrations. , 2001, Chaos.

[29]  G. Gallick,et al.  Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players , 2008, Clinical Cancer Research.

[30]  Melissa J. Davis,et al.  Gene regulatory network inference: evaluation and application to ovarian cancer allows the prioritization of drug targets , 2012, Genome Medicine.

[31]  Paola Lecca,et al.  Algorithmic Modeling Quantifies the Complementary Contribution of Metabolic Inhibitions to Gemcitabine Efficacy , 2012, PloS one.

[32]  D.G. Tzikas,et al.  The variational approximation for Bayesian inference , 2008, IEEE Signal Processing Magazine.

[33]  Takashi Kimura,et al.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma , 2011, Journal of hepato-biliary-pancreatic sciences.

[34]  Liang Zhiyong,et al.  Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines , 2009, Molecular Cancer.

[35]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Edward E. Whang,et al.  Identification of novel channel and transporter genes associated with acquired gemcitabine resistance in pancreatic adenocarcinoma cells. , 2003 .

[37]  I. Rusyn,et al.  Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry , 2008, Metabolomics.

[38]  Pasi Soininen,et al.  Quantitative high-throughput metabolomics: a new era in epidemiology and genetics , 2012, Genome Medicine.

[39]  中野 靖弘,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007 .

[40]  Ernst Wit.  Learning and Inference in Computational Systems Biology by LAWRENCE, N. D., GIROLAMI, M., RATTRAY, M., and SANGUINETTI, G , 2012 .

[41]  Godefridus J Peters,et al.  Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions , 2009, Scandinavian journal of gastroenterology.

[42]  D. Hedley,et al.  Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. , 2000, Cancer research.

[43]  Jos H. Beijnen,et al.  New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine , 2008, Molecular Cancer Therapeutics.

[44]  Bertram Klinger,et al.  Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS , 2012, Molecular systems biology.

[45]  Paola Lecca,et al.  Modelling and Estimating Dynamics of Tumor Shrinkage with BlenX and Kinfer , 2011, 2011 UkSim 13th International Conference on Computer Modelling and Simulation.

[46]  M. Opper,et al.  Bayesian Time Series Models: Approximate inference for continuous-time Markov processes , 2011 .

[47]  Tetsuo Arakawa,et al.  Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer , 2009, Journal of experimental & clinical cancer research : CR.

[48]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.